Applying the technology to reach your target

Apart from matching the technical needs of your tracer, fluorescence imaging needs to be practicable if it is to achieve its potential as an intraoperative confidence booster. SurgVision helps you apply the technology to reach that target.

An important goal of fluorescence imaging is to provide information that supports the surgeon in reducing positive margins after surgery. This improves the prognosis for the patient in terms of post-operative treatment and residual organ function; and by minimizing the need for re-excision it reduces health care costs. Providing feasible surgical support needs an imaging solution that

  • Fits with the surgical process, and
  • Handles the specifics of the anatomical site.

We have developed the SurgVision platform technology with an understanding of the need for adaptability that can successfully align the camera system with the specific needs of your tracer development. The camera and light can be adapted to complement your application.

In short, the SurgVision platform technology has the flexibility to fit the way you intend to apply it.

Adjustable for your results

We designed the camera of our platform technology for ease of modification.

  • The excitation light source can be adjusted to fit the needs of your tracer.

For example, the fluorescence characteristics (light source, as well as the detection and processing spectra) can be adjusted to fit the needs of your tracer and imaging, as we did for a folate receptor-α targeted fluorescent agent (fluorescein isothiocyanate (folate-FITC)), as described in the article "Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor- α targeting: first in-human results". (van Dam, G.M., et al., Nature Medicine. 2011 vol. 17, 1315–1319)

  • We can adapt the mechanism for exciting tissue, and acquiring the resulting signal, for use
    • in endoscopy
    • in laparoscopy.

Proving its value

Work in progress in three different clinical trials includes using a near-infrared (NIR) fluorescence endoscopy platform developed on the SurgVision platform technology. This supports them in clinical studies to apply a fluorescent tracer (bevacizumab-IDRye800CW) that targets vascular endothelial growth factor (VEGF) in

  • Detecting adenomas during surveillance endoscopy (NCT02113202),
  • Providing early visualization of esophageal (pre)malignant lesions (NCT02129933), and
  • Evaluating the response of patients with colorectal cancer to chemoradiotherapy (NCT01972373; published as Tjalma, J.J., Garcia-Allende, P.B. et al. Molecular Fluorescence Endoscopy Targeting Vascular Endothelial Growth Factor A for Improved Colorectal Polyp Detection. J Nucl Med. 2016 vol. 57 no. 3 480-485.).

This sample images were taken using the endoscope customization of the SurgVision platform technology.

a) White-light imaging from the endoscope, note the tip of the SurgVision fiber bundle marked with an *
b) Near infrared fluorescence image
c) Overlay image of white light and NIRF images from the fiber

This research was originally published in JNM. © by the Society of Nuclear Medicine and Molecular Imaging, Inc.